0001070081-20-000057.txt : 20200207
0001070081-20-000057.hdr.sgml : 20200207
20200207164111
ACCESSION NUMBER: 0001070081-20-000057
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200205
FILED AS OF DATE: 20200207
DATE AS OF CHANGE: 20200207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Almstead Neil Gregory
CENTRAL INDEX KEY: 0001578850
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35969
FILM NUMBER: 20588010
MAIL ADDRESS:
STREET 1: C/O PTC THERAPEUTICS, INC.
STREET 2: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001070081
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043416587
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080-2449
BUSINESS PHONE: 9082227000
MAIL ADDRESS:
STREET 1: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080-2449
FORMER COMPANY:
FORMER CONFORMED NAME: PTC THERAPEUTICS INC
DATE OF NAME CHANGE: 19980909
4
1
wf-form4_158111165404736.xml
FORM 4
X0306
4
2020-02-05
0
0001070081
PTC THERAPEUTICS, INC.
PTCT
0001578850
Almstead Neil Gregory
C/O PTC THERAPEUTICS, INC.
100 CORPORATE COURT
SOUTH PLAINFIELD
NJ
07080
0
1
0
0
Chief Technical Ops Officer
Common Stock
2020-02-06
4
M
0
46898
10.85
A
73987
D
Common Stock
2020-02-06
4
S
0
46898
55
D
27089
D
Common Stock
2020-02-06
4
M
0
3102
10.85
A
30191
D
Common Stock
2020-02-06
4
S
0
3102
55
D
27089
D
Common Stock
2020-02-05
4
S
0
405
55
D
5952
I
By spouse
Common Stock
2020-02-06
4
S
0
4040
55
D
1912
I
By spouse
Stock Option (Right To Buy)
10.85
2020-02-06
4
M
0
46898
10.85
D
2023-05-15
Common Stock
46898.0
0
D
Stock Option (Right To Buy)
10.85
2020-02-06
4
M
0
3102
10.85
D
2023-05-15
Common Stock
3102.0
0
D
Stock Option (Right To Buy)
490.8
2021-04-27
Common Stock
216.0
216
D
Stock Option (Right To Buy)
218.4
2022-01-10
Common Stock
166.0
166
D
Stock Option (Right To Buy)
27.05
2024-01-27
Common Stock
40000.0
40000
D
Stock Option (Right To Buy)
51.0
2025-01-01
Common Stock
69550.0
69550
D
Stock Option (Right To Buy)
30.86
2026-01-03
Common Stock
55000.0
55000
D
Stock Option (Right To Buy)
11.23
2027-01-02
Common Stock
35000.0
35000
D
Stock Option (Right To Buy)
18.01
2028-01-02
Common Stock
70000.0
70000
D
Stock Option (Right To Buy)
33.02
2029-01-21
Common Stock
72500.0
72500
D
Stock Option (Right To Buy)
33.02
2029-01-21
Common Stock
17500.0
17500
D
Stock Option (Right To Buy)
51.16
2030-01-28
Common Stock
69500.0
69500
D
The transactions reported in this Form 4 were effected pursuant to written Rule 10b5-1 plans.
Currently exercisable.
This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
/s/ Avraham S. Adler, attorney-in-fact
2020-02-07